Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran [5]

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 1, 2003, Pages 137-138

  Arai, M ^a  

^a SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CARBIDOPA; DOPAMINE; ETIDRONIC ACID; LEVODOPA; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AGED; CASE REPORT; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DOPAMINE RELEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MOTOR PERFORMANCE; OSTEOPOROSIS; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR DENSITY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; PARKINSON DISEASE, SECONDARY; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; TREMOR;

EID: 0037228324     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.1.137     Document Type: Letter

References (5)

1. Spencer CM, Wilde MI. Milnacipran. A review of its use in depression. Drugs 1998;56:405-27.
2. Celey CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 1997;31:1481-9.
3. Di Rocco A, Brannan T, Prikhojan A, et al. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998;105:247-51.
4. IA receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001;39:288-96.
5. Rogóz Z, Margas W, Dlaboga D, et al. Effect of repeated treatment with milnacipran on the central dopaminergic system. Pol J Pharmacol 2000;52:83-92.